Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for Outcome Of Board Meeting Held On December 20, 2021 And Compliance Of Regulations 29 And 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 1.To issue equity shares and/or warrants convertible into equity shares on preferential basis at Rs. 177.15/- to the following Promoters to meet the long term working capital requirements, general corporate purpose and such other purpose as the Board may decide. Sr. No. Name Warrants (No) Category 1. Mr. Mukund Mehta 2,50,000 Promoter 2. Mr. Bhavin Mehta 2,50,000 Promoter The issue price has been determined in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. * Note: Every warrant is entitled to receive 1 equity share at the time of conversion. 2.Convening Extra-Ordinary General Meeting of the members of the Company on Wednesday, 19th January, 2022 at 01:00 P.M. through Video Conference ('VC')/ Other Audio Visual Means ('OAVM') ('hereinafter referred to as 'electronic mode').
20-12-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window

 Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE,and the Company's Code for Insider Trading & Fair Disclosure of Unpublished Price Sensitive Information, the Trading Window will be closed with effect from 16th December, 2021 to 22th December, 2021. During the aforesaid period when the Trading Window is closed, designated persons including Promoters, Directors, connected persons, the insiders and their immediate relatives shall not trade in Company''s shares / securities.
15-12-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for To Issue Shares Warrants Convertible Into Equity Shares Through Preferential Allotment To Promoters Of The Company

 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/12/2021 ,inter alia, to consider and approve ?To issue Shares Warrants convertible into Equity Shares through Preferential Allotment to Promoters of the Company, and pursuant to applicable provisions of the Companies Act, 2013 along with applicable SEBI (LODR) Regulations, 2015, SEBI (ICDR) Regulations, 2018, as updated from time to time, subject to the approval of members of the Company. ?To consider conducting EGM of the Company with respect to the above referred matter pursuant to applicable provisions of the Companies Act, 2013 and approve the notice of the same. ?To appoint M/s Deep Shukla and Associates, Practising Company Secretary as the Srutinizer of the Company for the process of E-voting. ?Any other matter with the permission of the Chair.
15-12-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Disclosure Of Related Party Transaction Pursuant To Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 23(9) of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transaction on consolidated basis for the half year ended 30th September, 2021, in the format specified on the relevant accounting standards.
30-11-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Outcome Of Board Meeting Held On 12Th November, 2021

 In continuation to our letter dated 2nd November 2021, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 12th November, 2021, have considered and approved the following- 1.The Un-audited financial results of the company for the quarter and half year ended 30th September 2021;
12-11-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Outcome Of Board Meeting Held On 12Th November, 2021

 In continuation to our letter dated 2nd November 2021, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 12th November, 2021, have considered and approved the following- 1.The Un-audited financial results of the company for the quarter and half year ended 30th September 2021;
12-11-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th November, 2021

 In continuation to our letter dated 2nd November 2021, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 12th November, 2021, have considered and approved the following- 1.The Un-audited financial results of the company for the quarter and half year ended 30th September 2021;
12-11-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Board Meeting Intimation for Intimation Of Board Meeting For The Approval Of The Un-Audited Financial Results Of The Company For The Quarter/ Half Year Ended September 30, 2021

 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve ?To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter / half year ended September 30, 2021. ?Any other matter with the permission of the Chair.
02-11-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for Outcome Of Board Meeting Held On October 13, 2021

 We wish to inform you that we have Considered and approved the appointment of Ms. Princy Asati (ACS 65847) as the Company Secretary and Compliance Officer of the Company in place of Ms. Garima Trivedi ( ACS 62636) w.e.f 13th October , 2021. Approved the allotment of 20,305 Stock Option to Employees of the Company and Subsidiary Companies pursuant to Kilitch Employee Stock Option Scheme 2007. Taken Note of the Grant of 1,05,264 ESOPs on 13th October 2021 to 155 employees of the Company and Subsidiary Companies, under the Kilitch Employee Stock Option Scheme 2020 ("ESOP 2020") at an exercise price of 145/- per stock option vide a resolution passed by the Nomination and Remuneration Committee in its meeting held on 13th October, 2021. Each of the ESOPs entitles the holder to apply for one Equity Share of the Company of INR 10/- each. The meeting commenced at 12:30 P.M. (IST) and concluded at 4:05 P.M.(IST)
13-10-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith certificate issued by the Registrar & Share Transfer Agent M/s. Link Intime India Private Limited confirming the compliance of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018. This is for your information and records.
11-10-2021
Next Page
Close

Let's Open Free Demat Account